201 related articles for article (PubMed ID: 37341005)
1. Feasibility of artificial intelligence-based decision supporting system in tolvaptan prescription for autosomal dominant polycystic kidney disease.
Shin JH; Kim YH; Lee MK; Min HS; Cho H; Kim H; Kim YC; Lee YS; Shin TY
Investig Clin Urol; 2023 May; 64(3):255-264. PubMed ID: 37341005
[TBL] [Abstract][Full Text] [Related]
2. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
Chebib FT; Torres VE
Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
[TBL] [Abstract][Full Text] [Related]
3. Effect of Averaging Measurements From Multiple MRI Pulse Sequences on Kidney Volume Reproducibility in Autosomal Dominant Polycystic Kidney Disease.
Dev H; Zhu C; Sharbatdaran A; Raza SI; Wang SJ; Romano DJ; Goel A; Teichman K; Moghadam MC; Shih G; Blumenfeld JD; Shimonov D; Chevalier JM; Prince MR
J Magn Reson Imaging; 2023 Oct; 58(4):1153-1160. PubMed ID: 36645114
[TBL] [Abstract][Full Text] [Related]
4. Automated Kidney and Liver Segmentation in MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease: A Multicenter Study.
Woznicki P; Siedek F; van Gastel MDA; Dos Santos DP; Arjune S; Karner LA; Meyer F; Caldeira LL; Persigehl T; Gansevoort RT; Grundmann F; Baessler B; Müller RU
Kidney360; 2022 Dec; 3(12):2048-2058. PubMed ID: 36591351
[TBL] [Abstract][Full Text] [Related]
5. Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease.
Iijima H; Tada T; Hashimoto M; Nishimura T; Kiriki M; Higashiura A; Iwasaki A; Honda M; Nagasawa Y; Yamakado K
J Med Ultrason (2001); 2023 Jan; 50(1):81-87. PubMed ID: 36333536
[TBL] [Abstract][Full Text] [Related]
6. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
Moriyama T; Nakayama Y; Soejima M; Yokota Y; Ota K; Ito S; Kodama G; Nakamura N; Kurokawa Y; Yano J; Ueda U; Takamiya Y; Kaida Y; Hazama T; Shibata R; Koda Y; Fukami K
Clin Exp Nephrol; 2021 Mar; 25(3):251-260. PubMed ID: 33141305
[TBL] [Abstract][Full Text] [Related]
7. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
[TBL] [Abstract][Full Text] [Related]
8. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
9. Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis.
Lioudis M; Zhou X; Davenport E; Nunna S; Krasa HB; Oberdhan D; Fernandes AW
BMC Nephrol; 2023 Jun; 24(1):182. PubMed ID: 37349694
[TBL] [Abstract][Full Text] [Related]
10. A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease.
Simms RJ; Doshi T; Metherall P; Ryan D; Wright P; Gruel N; van Gastel MDA; Gansevoort RT; Tindale W; Ong ACM
Eur Radiol; 2019 Aug; 29(8):4188-4197. PubMed ID: 30666443
[TBL] [Abstract][Full Text] [Related]
11. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
Bennett H; McEwan P; Hamilton K; O'Reilly K
BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
[TBL] [Abstract][Full Text] [Related]
12. Automated measurement of total kidney volume from 3D ultrasound images of patients affected by polycystic kidney disease and comparison to MR measurements.
Jagtap JM; Gregory AV; Homes HL; Wright DE; Edwards ME; Akkus Z; Erickson BJ; Kline TL
Abdom Radiol (NY); 2022 Jul; 47(7):2408-2419. PubMed ID: 35476147
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics associated with 1-year tolvaptan efficacy in autosomal dominant polycystic kidney disease with a wide range of kidney functions.
Murakami T; Nishimura K; Ono H; Ueta S; Shibata E; Kishi S; Tamaki M; Miya K; Shima H; Tashiro M; Inoue T; Kawahara K; Nagai K; Abe H; Minakuchi J; Doi T
J Med Invest; 2020; 67(3.4):315-320. PubMed ID: 33148908
[TBL] [Abstract][Full Text] [Related]
14. Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease.
van Gastel MDA; Edwards ME; Torres VE; Erickson BJ; Gansevoort RT; Kline TL
J Am Soc Nephrol; 2019 Aug; 30(8):1514-1522. PubMed ID: 31270136
[TBL] [Abstract][Full Text] [Related]
15. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
Cornec-Le Gall E; Blais JD; Irazabal MV; Devuyst O; Gansevoort RT; Perrone RD; Chapman AB; Czerwiec FS; Ouyang J; Heyer CM; Senum SR; Le Meur Y; Torres VE; Harris PC
Nephrol Dial Transplant; 2018 Apr; 33(4):645-652. PubMed ID: 28992127
[TBL] [Abstract][Full Text] [Related]
16. A Deep Learning Approach for Automated Segmentation of Kidneys and Exophytic Cysts in Individuals with Autosomal Dominant Polycystic Kidney Disease.
Kim Y; Tao C; Kim H; Oh GY; Ko J; Bae KT
J Am Soc Nephrol; 2022 Aug; 33(8):1581-1589. PubMed ID: 35768178
[TBL] [Abstract][Full Text] [Related]
17. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
[TBL] [Abstract][Full Text] [Related]
18. Novel three-dimensional imaging volumetry in autosomal dominant polycystic kidney disease: comparison with 2D volumetry.
Shin D; Lee KB; Hyun YY; Lee YR; Hwang YH; Park HC; Ahn C
Clin Nephrol; 2014 Aug; 82(2):98-106. PubMed ID: 25029513
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.
Li X; Li W; Li Y; Dong C; Zhu P
Nefrologia (Engl Ed); 2023; 43(6):731-741. PubMed ID: 37150675
[TBL] [Abstract][Full Text] [Related]
20. Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
Higashihara E; Horie S; Muto S; Kawano H; Tambo M; Yamaguchi T; Taguchi S; Kaname S; Yokoyama K; Yoshioka T; Furukawa T; Fukuhara H
Am J Nephrol; 2020; 51(11):881-890. PubMed ID: 33227802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
